The prevalence of type 2 diabetes (T2DM) and cardiovascular disease (CVD) continues to escalate globally. There is now abundant clinical trial evidence that the optimal treatment of CVD risk factors, with lifestyle changes aimed at weight loss in most patients, and pharmacologic management of dyslipidemia and hyperglycemia, can help mitigate the CVD burden. Yet more than 50% of patients are still not achieving glycosylated hemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-C) goals. Over the past 15 years, many novel and emerging drugs have made it possible to achieve optimal glycemic control, generally in combination therapy, without untoward effects of weight gain, hypoglycemia, and other adverse effects with traditional agents. Although the long-term efficacy and safety of some of the newer classes of agents are yet to be determined, bile acid sequestrants represent a unique long-standing class of agents. These drugs have the dual efficacy in glycemic control and LDL-C reduction, and an established record of long-term safety. Colesevelam HCl is the only drug approved for this dual indication and is an adjunct in the treatment of both hyperglycemia and hypercholesterolemia that frequently co-exist in adults with T2DM.
Get full access to this article
View all access options for this article.
References
1.
FordES, AjaniUA, CroftJB, CritchleyJA, LabartheDR, KottkeTE, Giles CapewellS. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med, 2007; 356:2388–2398.
2.
BoothGL, KapralMK, FungK, TuJV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet, 2006; 368:29–36.
3.
DonahoeSM, StewartGC, McCabeCH, MohanaveluS, MurphySA, CannonCP, AntmanEM. Diabetes and mortality following acute coronary syndromes. JAMA, 2007; 298:765–775.
4.
HuFB, StampferMJ, HaffnerSM, SolomonCG, WillettWC, MansonJE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care, 2002; 25:1129–1134.
5.
MozaffarianD, MarfisiR, LevantesiG, SillettaMG, TavazziL, TognoniG, ValagussaF, MarchialiR. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet, 2007; 370:667–675.
6.
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet, 2008; 371:117–125.
7.
CannonCP, SteinbergBA, MurphySA, MegaJL, BraunwaldE. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol, 2006; 48:438–445.
8.
RidkerPM, DanielsonE, FonsecaFA, GenestJ, GottoAM, KasteleinJJP, KoenigW, LibbyP, LorenzattiAJ, MacFadyenJG, NordestgaardBG, ShepherdJ, WillersonJT>GlynnRJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med., 2008; 359:2195–2207.
9.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352:854–865.
10.
SelvinE, MarinopoulosS, BerkenblitG, RamiT, BrancatiFL, PoweNR, GoldenSH. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med, 2004; 141:421–431.
11.
MatsushitaK, BleckerS, Pazin-FilhoA, BertoniA, ChangPP, CoreshJ, SelvinE. The Association of hemoglobin A1c with incident heart failure among people without diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes, 2010; 59:2020–2026.
12.
CurrieCJ, PetersJR, TynanA, EvansM, HeineRJ, BraccoOL, ZagarT, PooleC. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet, 2010; 375:481–489.
13.
NathanDM, ClearyPA, BacklundJY, GenuthSM, LachinJM, OrchardTJ, RaskinP, ZinmanB. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353:2643–2653.
14.
HolmanRR, PaulSK, BethelMA, MatthewsDDR, NeilHAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
15.
Action to Control Cardiovascular Risk in Diabetes Study Group. GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-BeigiF, GrimmRH, ProbstfieldJL, Simons-MortonDG, FriedewaldWT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
16.
ADVANCE Collaborative Group. PatelA, MacMahonS, ChalmersJ, NealB, BillotL, WoodwardM, MarreM, CooperM, GlasziouP, GrobbeeD, HametP, HarrapS, LiuLS, ManciaG, MogensenCE, PanCY, PoulterN, RodgersA, WilliamsB, BompointS, de GalanBE, JoshiR, TravertF, FassettR. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008; 358:2560–2572.
17.
DuckworthW, AbrairaC, MoritzT, RedaD, EmanueleN, ReavenPD, ZieveFJ, MarksJ, DavisSN, HaywardR, WarrenSR, GoldmanS, McCarrenM, VitekME, HendersonWG, HuangGD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360:129–139.
18.
GogitidzeJN, HedringtonMS, BriscoeVJ, TateDB, ErtlAC, DavisSN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care, 2010; 33:1529–1535.
19.
WrightRN, NewbyDE, StirlingD, LudlamCA, MacdonaldIA, FrierBM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care, 2010; 33:1591–1597.
20.
RiddleMC, AmbrosiusWT, BrillonDJ, BuseJB, ByingtonRP, CohenRM, GoffDCJr, MalozowskiS, MargolisKL, ProbstfieldJL, SchnallA, SeaquistER. for the Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care, 2010; 33:983–990.
21.
CheungBM, OngKL, ChernySS, ShamPC, TsoAW, LamKS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med., 2009; 122:443–453.
22.
Standards of medical care in diabetes—2010. Diabetes Care, 2010; 33,Suppl 1:S11–S61.
23.
RatnerR, GoldbergR, HaffnerS, MarcovinaS, OrchardT, FowlerS, TemprosaM. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care, 2005; 28:888–894.
24.
Pi-SunyerX, BlackburnG, BrancatiFL, BrayGA, BrightR, ClarkJM. et al.Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial. Diabetes Care, 2007; 30:1374–1383.
25.
BelalcazarLM, ReboussinDM, HaffnerSM, HoogeveenRCet al.A one-year lifestyle intervention for weight loss in persons with type 2 diabetes reduces high c-reactive protein levels and identifies metabolic predictors of change, from the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care, 2010[Epub ahead of print; 10.2337/dc10-0728].
26.
LazoM, SolgaSF, HorskaA, BonekampS, DiehlS, BrancatiFL, WagenknechtLE, Pi-SunyerFX, KahnSE, ClarkJM. for the Fatty Liver Subgroup of the Look AHEAD Research Group. The effect of a 12-month Intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes CareEpub of print July 27, 201010.2337/dc10-0856.
27.
SjostromL, NarbroK, SjostromCD, KarasonK, LarssonB, WedelH, LystigT, SullivanM, BouchardC, CarlssonB, BengtssonC, DahlgrenS, GummessonA, JacobsonP, KarlssonJ, LindroosAK, LonrothAK, NaslundI, OlbersT, StenlofK, TorgersonJ, AgrenG, CarlssonLM. Swedis Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med, 2007; 357:741–752.
28.
IllingworthDR. An overview of lipid-lowering drugs. Drugs, 1988; 36,Suppl 3:63–71.
29.
Alsheikh-AliAA, MaddukuriPV, HanH, KarasRH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol, 2007; 50:409–418.
30.
ArmitageJ. The safety of statins in clinical practice. Lancet, 2007; 370:1781–1790.
31.
GagneC, BaysHE, WeissSR, MataP, QuintoK, MelinoM, ChoM, MuslinerTA, GumbinerB. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol, 2002; 90:1084–1091.
32.
KnappHH, SchrottH, MaP, KnoppR, ChinB, GazianoJM, DonovanJM, BurkeSK, DavidsonMH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med, 2001; 110:352–360.
33.
InsullWJr.Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J, 2006; 99:257–273.
34.
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 1984; 251:365–374.
35.
GargA, GrundySM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med, 1994; 121:416–422.
36.
KobayashiM, IkegamiH, FujisawaT, NojimaK, KawabataY, NosoS, NosoS, BabayaN, Itoi-BabayaM, YamajiK, HiromineY, ShibataM, OgiharaT. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes, 2007; 56:239–247.
37.
NathanDM, BuseJB, DavidsonMB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009; 32:193–203.
38.
RodbardH, JellingerP, DavidsonJA, EinhornD, GarberAJ, GrunbergerG, HandelsmanY, HortonES, LebovitzH, LevyP, MoghissiES, SchwartzSS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract, 2009; 15:540–559.
39.
SherifaliD, NerenbergK, PullenayegumE, ChengJE, GersteinHC. The effect of oral antidiabetic agents on A1C levels. Diabetes Care, 2010; 33:1859–1864.
40.
JialalI, AbbySL, MisirS, NagendranS. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: A pooled analysis. Metab Syndr Relat Disord, 2009; 7:255–258.
41.
HanefeldM, CagatayM, PetrowitschT, NeuserD, PetzinnaD, RuppM. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J, 2004; 25:10–16.
